Bilaketaren emaitzak - Naidoo, Jarushka

PD-1 and PD-L1 inhibitor toxicities in non-small cell lung cancer nork Shankar, Bairavi, Naidoo, Jarushka

Testu osoa Testu osoa Testu osoa

A Multidisciplinary Approach for Patients with Preexisting Lung Diseases and Immune Checkpoint Inhibitor Toxicities nork Naidoo, Jarushka, Suresh, Karthik

Testu osoa Testu osoa Testu osoa

Immunotherapy for Stage III NSCLC: Durvalumab and Beyond nork Fitzpatrick, Orla, Naidoo, Jarushka

Testu osoa Testu osoa Testu osoa

Immune-related adverse events and the balancing act of immunotherapy nork Conroy, Michael, Naidoo, Jarushka

Testu osoa Testu osoa Testu osoa

Immune-Related Adverse Events: A Case-Based Approach nork Connolly, Caoilfhionn, Bambhania, Kalindi, Naidoo, Jarushka

Testu osoa Testu osoa Testu osoa

4401 Incidence, management, and outcomes of immune-related adverse events (irAEs): an analysis of a multidisciplinary toxicity team for cancer immunotherapy related irAEs nork Balaji, Aanika, Zhang, Jiajia, Naidoo, Jarushka

Testu osoa Testu osoa

An adapted anti-CTLA4 therapeutic aimed at mitigating the toxicities of checkpoint inhibition nork Naidoo, Jarushka, Dykema, Arbor, D’Alessio, Franco

Testu osoa Testu osoa Testu osoa

Successful Treatment of Scar Pain with Scrambler Therapy nork Yarchoan, Mark, Naidoo, Jarushka, Smith, Thomas J

Testu osoa Testu osoa Testu osoa

Treatment of Complications from Immune Checkpoint Inhibition in Patients with Lung Cancer nork Wills, Beatriz, Brahmer, Julie R., Naidoo, Jarushka

Testu osoa Testu osoa Testu osoa

What does the future hold for immunotherapy in cancer? nork Naidoo, Jarushka, Li, Bob T., Schindler, Katja, Page, David B.

Testu osoa Testu osoa Testu osoa

The 2014 San Antonio Breast Cancer Symposium: A successful lift-off for breast immunotherapy? nork Page, David B, Naidoo, Jarushka, McArthur, Heather L

Testu osoa Testu osoa

Immune Checkpoint Immunotherapy for Non-Small Cell Lung Cancer: Benefits and Pulmonary Toxicities nork Suresh, Karthik, Naidoo, Jarushka, Lin, Cheng Ting, Danoff, Sonye

Testu osoa Testu osoa Testu osoa

Immune-mediated ototoxicity associated with immune checkpoint inhibitors in patients with melanoma nork Rosner, Samuel, Agrawal, Yuri, Sun, Daniel Q, Aygun, Nafi, Schollenberger, Megan D, Lipson, Evan, Naidoo, Jarushka

Testu osoa Testu osoa Testu osoa

Cutaneous adverse events of immune checkpoint inhibitor therapy: incidence and types of reactive dermatoses nork Le, Thomas K., Kaul, Subuhi, Cappelli, Laura C., Naidoo, Jarushka, Semenov, Yevgeniy R., Kwatra, Shawn G.

Testu osoa Testu osoa Testu osoa

Patterns of long-term survival following Ipilimumab (Ipi): the Memorial Sloan Kettering Cancer Center 10-year metastatic melanoma (MM) experience nork Page, David B, Naidoo, Jarushka, Momtaz, Parisa, Bogatch, Kita, Kuk, Deborah, Panageas, Katherine, Yuan, Jianda, Wolchok, Jedd D, Postow, Michael

Testu osoa Testu osoa

2568 Pembrolizumab for patients with leptomeningeal disease from advanced solid tumors nork Naidoo, Jarushka, Hu, Chen, Schrek, Karisa, Connolly, Roisin, Santa-Maria, Cesar, Lipson, Evan, Mehra, Ranee, Bettegowda, Redmond, Kristin, Venkatesan, Arun, Grossman, Stuart

Testu osoa Testu osoa

The cost of cancer care: how far would you go for a trial? nork Fitzpatrick, Orla M., Murphy, Catherine, Duignan, Erica, Egan, Keith, Hennessy, Bryan T., Grogan, Liam, Murphy, Adrian, Breathnach, Oscar S., Naidoo, Jarushka, Morris, Patrick G.

Testu osoa Testu osoa Testu osoa

Clinical presentation of immune checkpoint inhibitor-induced inflammatory arthritis differs by immunotherapy regimen nork Cappelli, Laura C., Brahmer, Julie R., Forde, Patrick M., Le, Dung T., Lipson, Evan J., Naidoo, Jarushka, Zheng, Lei, Bingham, Clifton O., Shah, Ami A.

Testu osoa Testu osoa Testu osoa

Radiation Versus Immune Checkpoint Inhibitor Associated Pneumonitis: Distinct Radiologic Morphologies nork Chen, Xuguang, Sheikh, Khadija, Nakajima, Erica, Lin, Cheng Ting, Lee, Junghoon, Hu, Chen, Hales, Russell K., Forde, Patrick M., Naidoo, Jarushka, Voong, Khinh Ranh

Testu osoa Testu osoa Testu osoa

Adaptive neoadjuvant chemotherapy guided by (18)F-FDG-PET in resectable non-small-cell lung cancers: the NEOSCAN trial nork Chaft, Jamie E., Dunphy, Mark, Naidoo, Jarushka, Travis, William D., Hellmann, Matthew, Woo, Kaitlin, Downey, Robert, Rusch, Valerie, Ginsberg, Michelle S., Azzoli, Christopher G., Kris, Mark G.

Testu osoa Testu osoa Testu osoa